Pioglitazona [Inn-Spanish]
Brand names,
Pioglitazona [Inn-Spanish]
Analogs
Pioglitazona [Inn-Spanish]
Brand Names Mixture
Pioglitazona [Inn-Spanish]
Chemical_Formula
C19H20N2O3S
Pioglitazona [Inn-Spanish]
RX_link
http://www.rxlist.com/cgi/generic2/pioglit.htm
Pioglitazona [Inn-Spanish]
fda sheet
Pioglitazona [Inn-Spanish]
msds (material safety sheet)
Pioglitazona [Inn-Spanish]
Synthesis Reference
K. Meguro, T. Fujita, U.S. Pat. 4,687,777 (1987)
Pioglitazona [Inn-Spanish]
Molecular Weight
356.44 g/mol
Pioglitazona [Inn-Spanish]
Melting Point
183-184oC
Pioglitazona [Inn-Spanish]
H2O Solubility
mg/mL
Pioglitazona [Inn-Spanish]
State
Solid
Pioglitazona [Inn-Spanish]
LogP
No information avaliable
Pioglitazona [Inn-Spanish]
Dosage Forms
Oral tablets
Pioglitazona [Inn-Spanish]
Indication
Treatment of Type II diabetes mellitus
Pioglitazona [Inn-Spanish]
Pharmacology
Pioglitazone, a member of the drug group known as the thiazolidinediones or "insulin sensitizers", is not chemically or functionally related to the alpha-glucosidase inhibitors, the biguanides, or the sulfonylureas. Pioglitazone targets insulin resistance and, hence, is used alone or in combination with insulin, metformin, or asulfonylurea as an antidiabetic agent.
Pioglitazona [Inn-Spanish]
Absorption
Following oral administration, in the fasting state, pioglitazone is first measurable in serum within 30 minutes, with peak concentrations observed within 2 hours. Food slightly delays the time to peak serum concentration to 3 to 4 hours, but does not alter the extent of absorption.
Pioglitazona [Inn-Spanish]
side effects and Toxicity
Hypogycemia; LD50=mg/kg (orally in rat)
Pioglitazona [Inn-Spanish]
Patient Information
Pioglitazona [Inn-Spanish]
Organisms Affected
Humans and other mammals